By Peter M. Haddad, Serdar Dursun, Bill Deakin
Read or Download Adverse syndromes and psychiatric drugs: a clinical guide PDF
Similar clinical books
This concise pocket advisor to urological investigative approaches stories the symptoms and pitfalls of assessments sooner than they're asked and indicates which checks will be played in person urological stipulations. half I describes the foundations, method, merits and drawbacks of every of the investigations and covers all urological investigations/tests.
1 2 D. FITZGERALDI, I. PASTAN , and J. ROBERTUS advent . . . . . . . . . . . . . I 2 Toxin Structure-Function homes 2 2. 1 features. . . . . . . . . . . . . . . . . . . . . . . . 2 2. 2 Binding. . . . . . . . . . . . . . . . . . . . . . . . . three three Intracellular Processing - Cleavage and relief .
- Clinical Applications of Cytokines and Growth Factors
- Basic and Clinical Environmental Approaches in Landscape Planning
- Hospice and Palliative Care : Questions and Answers, 1st Edition
- Implantation: Biological and Clinical Aspects
- Parasitic Disease in Clinical Practice
Additional info for Adverse syndromes and psychiatric drugs: a clinical guide
1991). Another theory that attempts to explain the pathophysiology of NMS centres on the role of sympathoadrenal hyperactivity (Gurrera and Romero 1992; Gurrera 1999; Gurrera 2000). According to this model, a predisposition to extreme sympathetic nervous system hyperactivity may act as a trait vulnerability for NMS. In the presence of state variables, such as neuroleptic-induced DA system hypoactivity or psychological distress, this leads to the clinical picture of NMS. This model needs to be tested in clinical studies to verify its validity.
White DA (1992). Catatonia and the neuroleptic malignant syndrome – a single entity? Br J Psychiatry, 161, 558–60. qxd 5/5/04 5:37 PM Page 37 Chapter 3 Serotonin syndrome Ken Gillman and Ian M Whyte Introduction There have been many deaths caused by serotonin (5-hydroxytryptamine, 5-HT) toxicity (serotonin syndrome) approximately 50 of which have been described in the literature. This book will arrive in time to mark the fiftieth anniversary of the first of these reported fatalities (Mitchell 1955).
Am J Psychiatry, 148, 714–26. Wright P, Birkett M, David SR, et al. (2001). Double-blind, placebo-controlled comparison of intramuscular olanzapine and intramuscular haloperidol in the treatment of acute agitation in schizophrenia. Am J Psychiatry, 158, 1149–51. Youssef HA and Waddington JL (1987). Morbidity and mortality in tardive dyskinesia: associations in chronic schizophrenia. Acta Psychiatr Scand, 75, 74–7. qxd 5/5/04 5:33 PM Page 21 Chapter 2 Neuroleptic malignant syndrome Dora Kohen Neuroleptic malignant syndrome (NMS) is an increasingly rare but potentially fatal disorder.